Markets | |
By now you know that on August 14, the United States bond market saw the yield on 2-year Treasury notes climb above the yield on 10-year Treasury notes. The “2-10 spread” is a significant marker for analysts. An inversion in this spread has occurred in advance of the last nine recessio... Read the Full Story |
|
From Our Partners | | Your account is not currently signed up for MarketBeat's free Monday morning stock ideas. Our team is going to be releasing an important pick on Monday morning (at 11am ET) and we want to make sure that you are able to see it. | | Add your name to the distribution list here |
|
Markets | |
On a recent weekend trip, I was made aware that the future was closer to reality than I thought. While walking through the city, I did a double-take when my son said, “Dad, why does my phone say 5G?”
I took out my phone and there it was in the upper left-hand corner of my screen. Ins... Read the Full Story |
|
Markets | |
When you invest your money, knowledge is power. So, before making an investment in a company, you should always perform a fundamental analysis to evaluate a company's intrinsic value. When examining the company’s financial and economic data, make sure you understand its cash flow.
Much like... Read the Full Story |
|
From Our Partners | | Roger Scott just unveiled a day-trading tool designed to identify the first wave of institutional buying before a full order moves through the market - potentially in minutes.
On April 14th, the tool flagged early institutional buys on HOOD at 9:45 am, delivering a 24% return in 6 minutes. Minutes later, a signal on MSTR locked in a 33% return in 12 minutes. Free access is available now. | | Secure your free pass to the real-time institutional order tracker today |
|
The Early Bird Stock Of The Day Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California. | | View Today's Stock Pick |
|
